Tenalisib (RP6530) is primarily investigated for its application in the treatment of various cancers, particularly hematologic malignancies. It functions as a dual inhibitor of PI3K delta and gamma isoforms, which play crucial roles in the proliferation and survival of cancer cells. This makes it a promising candidate for targeting B-cell malignancies such as chronic lymphocytic leukemia (CLL), non-Hodgkin lymphoma (NHL), and other lymphoid cancers.

In clinical trials, Tenalisib has demonstrated potential in reducing tumor growth and improving patient outcomes by disrupting signaling pathways that cancer cells rely on. Its selective inhibition of PI3K delta and gamma also suggests a favorable safety profile compared to broader PI3K inhibitors, minimizing off-target effects.

Additionally, Tenalisib is being explored for its potential in autoimmune diseases, given the role of PI3K isoforms in immune cell activation. Its ability to modulate immune responses could make it a valuable therapeutic option for conditions like rheumatoid arthritis or lupus.

Overall, Tenalisib represents a targeted approach to cancer therapy and immune modulation, offering hope for more effective and safer treatments in these areas.